The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...

A new experimental vaccine could slow down triple negative breast cancer and reduce its recurrence after treatment.

Triple-negative breast cancer lacks key receptors, requiring chemotherapy, immunotherapy, surgery, and radiation, with treatment tailored to cancer stage. Early-stage TNBC treatment often involves ...

March 4, 2011 — Two of the largest studies to date looking at triple-negative breast cancer have found that reproductive factors — specifically, pregnancy and multiple childbirth — and obesity and ...

Enhancing care of patients with HR+/HER2- early breast cancer at high risk of recurrence through an expansive curriculum: Real world outcomes (RWO) from a 6 month analysis.

Triple-negative breast cancer is particularly aggressive and difficult to treat; but recent research may offer a new way to target the often-deadly disease. A team of researchers from the University ...

Triple negative breast cancer (TNBC) is one of the most aggressive and hardest forms of breast cancer to treat, but a new study led by Weill Cornell Medicine suggests a surprising way to stop it from ...

Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage ...

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.